EDITAS MEDICINE, INC. Impairment of Long-Lived Assets to be Disposed of
EDITAS MEDICINE, INC. (EDIT) reported Impairment of Long-Lived Assets to be Disposed of of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2026-08-05
- EDITAS MEDICINE, INC. impairment of long-lived assets to be disposed of for the quarter ending 2026-06-30 was $0.00.
- EDITAS MEDICINE, INC. impairment of long-lived assets to be disposed of for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. impairment of long-lived assets to be disposed of for the quarter ending 2025-12-31 was $34.00K.
- EDITAS MEDICINE, INC. impairment of long-lived assets to be disposed of for the quarter ending 2025-09-30 was $0.00.
- EDITAS MEDICINE, INC. impairment of long-lived assets to be disposed of for fiscal 2025 was $3.76M.
- EDITAS MEDICINE, INC. impairment of long-lived assets to be disposed of for fiscal 2024 was $0.00.
| Period end | Impairment of Long-Lived Assets to be Disposed of 3 month | Impairment of Long-Lived Assets to be Disposed of 6 month | Impairment of Long-Lived Assets to be Disposed of 9 month | Impairment of Long-Lived Assets to be Disposed of 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $34.00K derived: sum of 3 quarters · filed 2026-08-05 | $34.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $34.00K derived: sum of 2 quarters · filed 2026-05-05 | $34.00K derived: sum of 3 quarters · filed 2026-05-05 | $34.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $34.00K derived: sum of 2 quarters · filed 2026-03-09 | $34.00K derived: sum of 3 quarters · filed 2026-08-05 | $3.76M 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $3.72M 10-Q · filed 2025-11-10 | $3.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.72M 10-Q · filed 2026-08-05 | $3.72M derived: sum of 3 quarters · filed 2026-08-05 | $3.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.72M 10-Q · filed 2026-05-05 | $3.72M derived: sum of 2 quarters · filed 2026-05-05 | $3.72M derived: sum of 3 quarters · filed 2026-05-05 | $3.72M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |